The Patent Finder
US

Pharmaceutical Compositions and Related Methods of Delivery

US 11,400,159 In force
OverviewFamilyAssignmentsSources & methods

Term ends Sep 17, 2029 · Medium confidence

Filed Aug 11, 2020 as application 16/990,071 · Granted Aug 2, 2022
Base term, 20 years from filing
Today
20 years from filing
2009 2029
Clock starts
Sep 17, 2009
Term ends
Sep 17, 2029
Granted
Aug 2, 2022
base term fee events Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,329,198, US 8,535,695, US 9,265,812, US 9,566,246, to Sep 17, 2029. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
15
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Sep 17, 2009, when application 12/561,738, the earliest non-provisional in its chain, was filed (this one was filed Aug 11, 2020); a parent in its chain could not be resolved (the next row)Sep 17, 2029High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 8,329,198, US 8,535,695, US 9,265,812, US 9,566,246)resolves to Sep 17, 2029, no earlier than this term, so no changeMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 1 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderSep 17, 2029Medium confidence

This family

Application 12/561,738Abandoned
not computed
not computed
Application 12/981,036Abandoned
not computed
not computed
US 8,535,695In force
no later than Sep 2029
no later than Sep 2029
US 8,329,198In force
no later than Sep 2029
no later than Sep 2029
US 9,265,812In force
no later than Sep 2029
no later than Sep 2029
US 9,566,246In force
Sep 2029
Sep 2029
Application 15/981,423Abandoned
not computed
not computed
US 11,400,159this patent
Sep 2029
Sep 2029
8 of 15 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Nov 3, 2021
Reel 58009, frame 27
Chiasma, Inc.Amryt Endo, Inc.Merger
Nov 3, 2021
Reel 58014, frame 883
Salama, Paul; Mamluk, Roni; Marom, Karen; Weinstein, Irina; Tzabari, MosheChiasma, Inc.Assignment of Assignor's Interest
Feb 18, 2022
Reel 59048, frame 944
Amryt Endo, Inc.Ares Capital Corporation, As Administrative AgentSecurity Interest
Apr 13, 2023
Reel 63318, frame 849
Ares Capital Corporation, As Administrative AgentAmryt Pharmaceuticals, Inc.; Amryt Endo, Inc.; Amryt Research Limited; Amryt Genetics LimitedRelease of Security Interest
Apr 13, 2023
reel/frame not recorded
Ares Capital Corporation, As Administrative AgentAmryt Pharmaceuticals, Inc.Release of Security Interest
Apr 13, 2023
reel/frame not recorded
Ares Capital Corporation, As Administrative AgentAmryt Endo, Inc.Release of Security Interest
Apr 13, 2023
reel/frame not recorded
Ares Capital Corporation, As Administrative AgentAmryt Research LimitedRelease of Security Interest
Apr 13, 2023
reel/frame not recorded
Ares Capital Corporation, As Administrative AgentAmryt Genetics LimitedRelease of Security Interest
Mar 19, 2024
Reel 66833, frame 786
McEvoy, JohnAmryt Endo, Inc.Change of Address
Jan 7, 2026
Reel 73389, frame 551
Amryt Endo, Inc.; Amyrt Pharmaceuticals Inc.Amryt Pharmaceuticals Inc.Merger and Change of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited